Malaysian Civil Society Groups Seek Lawsuit to Regulate Vape Sales

Aug.21.2023
Three civil society groups in Malaysia have been granted permission to proceed with their lawsuit against the Health Minister and government over the sale of vape products to children.

Three civil society groups in Malaysia have been granted permission to proceed with their lawsuit against Health Minister Dr Zaliha Mustafa and the Malaysian government. The lawsuit aims to prevent the open selling of vape liquid and vape gels to children. The High Court's decision to grant leave means that the judge will continue to hear the case.

 

The three groups involved in the lawsuit are the Malaysian Council for Tobacco Control, the Malaysian Green Lung Association, and Voice of the Children Sdn Bhd. They had to first obtain the court's permission for the lawsuit to proceed. The government did not object to the application for leave, leading to the High Court granting permission.

 

One aspect of the lawsuit is an application for an interim stay on the health minister's order to remove e-cigarette and vape liquids from the Poisons List. The civil society groups argue that vape liquids should be temporarily included back under the Poisons List until the lawsuit is heard. This would regulate the sale of these products and prevent their open sale to children.

 

Lawyer Edmund Bon, representing the civil society groups, argued for an interim stay due to concerns about the danger to children's health and the potential increase in deaths and healthcare costs associated with e-cigarette and vape use. Bon also pointed out that the non-regulation of vape liquids means that nicotine levels are currently unregulated and legally permissible at any level.

 

The civil society groups previously claimed that the removal of vape liquids from the Poisons List was done to impose a tax on e-cigarette and vape liquids containing nicotine. The Finance Ministry had imposed an excise duty on these products from April 1 onwards. Bon argued that the government would not be financially harmed if the interim stay is granted, as taxes could still be collected if the civil society groups fail in their lawsuit.

 

The Attorney-General's Chambers objected to the interim stay application, stating that there are no special circumstances warranting a stay. However, Bon argued that there are special circumstances and that a stay is different from an injunction.

 

The High Court will make a decision on September 5 regarding the interim stay sought by the civil society groups.

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Bangladesh High Court rule targets vape-ban clause; fines up to about $1,635 cited
Bangladesh High Court rule targets vape-ban clause; fines up to about $1,635 cited
Bangladesh’s High Court issued a rule asking why Section 6(G) of the Smoking and Tobacco Products Usage (Control) Act, 2005 — which bans the import, supply and sale of vapes and e-cigarettes — should not be declared unconstitutional and illegal.
Mar.02 by 2FIRSTS.ai
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar announces ban on e-cigarettes, covering imports/exports, sales, possession and use
Myanmar’s Ministry of Health said it has received cabinet authorization to enforce an e-cigarette ban under the Essential Supplies and Services Law, listing prohibited acts including the import, export, sale, possession, storage, carrying, distribution and use of vaping products.
Feb.26 by 2FIRSTS.ai
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
Product | Refillable up to 30 mL in total and claimed 60,000 puffs: MASKKING launches open-system UCEE MAX
E-cigarette brand MASKKING has recently listed its new UCEE MAX on its official website. According to the website, the device features an open, refillable design with a stated 10 mL e-liquid capacity, supports three refills, and claims a total of 60,000 puffs.
Mar.02 by 2FIRSTS.ai
Malaysia maritime officers seize nearly 16,500 vapes in suspected cross-border smuggling bid
Malaysia maritime officers seize nearly 16,500 vapes in suspected cross-border smuggling bid
According to Malay Mail and Bernama, Malaysia’s maritime enforcement agency intercepted a suspicious lorry at a jetty in Kedah’s Kuala Sanglang and seized nearly 16,500 vape devices worth more than RM500,000 (about US$125,000). Three men were detained for investigation, and the case is being probed under Malaysia’s Customs Act 1967.
Mar.09 by 2FIRSTS.ai
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
Small ENDS Manufacturers Press FDA on Abuse Liability Standards as Agency Defines Pharmacological Review Framework
At the third session of its PMTA roundtable, the FDA outlined its framework for assessing abuse liability in ENDS products, emphasizing the role of nicotine pharmacokinetics and product-specific data in APPH determinations. Small manufacturers questioned the high cost of clinical PK studies and the absence of defined numeric thresholds, while raising bridging strategies and PBPK modeling as potential alternatives.
Feb.11